Saizen® (r-hGH) Phase 3 study evaluates safety and efficacy in children with Idiopathic Short Stature
Background
Idiopathic Short Stature (ISS) is a diagnosis given to children who are significantly shorter than their peers without an identifiable medical cause, genetic syndrome, or endocrine disorder like growth hormone deficiency. It affects approximately 3-5% of children, leading to potential psychosocial challenges and reduced quality of life. Current management often involves recombinant human growth hormone (r-hGH) therapy, which aims to increase final adult height. However, the efficacy and long-term safety profile, particularly for specific dosing regimens in ISS, require rigorous evaluation through large-scale clinical trials to establish optimal treatment protocols and ensure patient benefit.
Study Design
This was a randomized, open-label, two-arm parallel group, no-treatment group-controlled, multicenter Phase 3 study. It enrolled 90 children diagnosed with Idiopathic Short Stature (ISS). Participants were assigned to one of two groups: a Saizen Test Group or a Saizen Control Group. The test group received Saizen® (recombinant-human growth hormone) subcutaneously at a dose of 0.067 mg/kg/day for 12 months, administered 6 days per week. The control group received no treatment for the initial 6 months, after which they also received Saizen® at the same 0.067 mg/kg/day dose for the subsequent 6 months. The study aimed to evaluate the safety and efficacy of this specific Saizen® regimen.
Why It Matters
A successful Phase 3 trial of Saizen® for Idiopathic Short Stature (ISS) could significantly impact pediatric endocrinology by providing robust evidence for a standardized and effective treatment protocol. For clinicians, it would offer clearer guidelines on the use of recombinant human growth hormone in children who do not meet criteria for growth hormone deficiency but still experience significant short stature. Establishing the safety and efficacy of Saizen® at this specific dose could lead to improved growth outcomes and quality of life for affected children. While results are pending, positive findings would support broader clinical adoption and potentially refine existing treatment paradigms, moving closer to a definitive, evidence-based approach for this challenging condition.